Virtual Library
Start Your Search
Zhe Liu
Author of
-
+
JCSE01 - Perspectives for Lung Cancer Early Detection (ID 779)
- Event: WCLC 2018
- Type: Joint IASLC/CSCO/CAALC Session
- Track: Screening and Early Detection
- Presentations: 1
- Moderators:
- Coordinates: 9/23/2018, 07:30 - 11:15, Room 202 BD
-
+
JCSE01.22a - Tislelizumab Combined With Chemotherapy as First-Line Treatment in Chinese Patients With Advanced Lung Cancer (ID 14702)
11:15 - 11:15 | Author(s): Zhe Liu
- Abstract
Abstract not provided
-
+
P1.04 - Immunooncology (Not CME Accredited Session) (ID 936)
- Event: WCLC 2018
- Type: Poster Viewing in the Exhibit Hall
- Track:
- Presentations: 1
- Moderators:
- Coordinates: 9/24/2018, 16:45 - 18:00, Exhibit Hall
-
+
P1.04-36 - Tislelizumab Combined With Chemotherapy as First-Line Treatment in Chinese Patients With Advanced Lung Cancer (ID 12092)
16:45 - 18:00 | Author(s): Zhe Liu
- Abstract
Background
Immune checkpoint inhibitors have shown efficacy in patients with NSCLC as monotherapy and in combination with chemotherapy. Tislelizumab is a humanized IgG4 monoclonal antibody to PD‑1 specifically engineered to minimize FcϒR binding on macrophages, possibly minimizing negative interactions with other immune cells. In a phase 1 study, tislelizumab was generally well tolerated and showed antitumor activity; 200mg IV Q3W was established as the recommended dose.
a9ded1e5ce5d75814730bb4caaf49419 Method
This multi-arm phase 2 study, consisting of safety run-in and dose-extension phases, assessed tislelizumab in combination with platinum-based chemotherapy (by tumor histology) as a potential first-line treatment for Chinese patients with lung cancer. All patients received tislelizumab at 200mg Q3W in combination with 4–6 cycles of platinum-doublet until disease progression. Nonsquamous (nsq) NSCLC patients received pemetrexed + platinum Q3W for 4 cycles followed by pemetrexed maintenance, while squamous (sq) NSCLC patients received paclitaxel + platinum (A) or gemcitabine + platinum (B) Q3W, and small-cell lung cancer (SCLC) patients received etoposide + platinum Q3W. Tumor response (RECIST v1.1) and safety/tolerability were evaluated.
4c3880bb027f159e801041b1021e88e8 Result
As of 21 Feb 2018, 48 patients (median age, 62 years [range: 36–75], 71% male, 71% current/former smokers) received tislelizumab treatment (median, 3 cycles [range: 1–7]); 44 patients remain on the study. Across the four cohorts, confirmed and unconfirmed partial responses were observed in 13 and 9 patients, respectively (Table). The most frequent AEs were chemotherapy-related hematologic toxicities. The most commonly reported grade ≥3 treatment-related AEs were neutropenia (20.8%) and anemia (12.5%); the most common grade 3 immune-related AEs were pyrexia (6.3%) and rash (6.3%). One sq‑NSCLC patient experienced a fatal myocarditis/myositis following one cycle of paclitaxel/cisplatin; all other treatment-related AEs were managed/resolved by study-drug interruption (n=15) or discontinuation (n=4) and appropriate treatment.
8eea62084ca7e541d918e823422bd82e ConclusionBest Overall Response (Patients With ≥1 Post-Baseline Tumor Assessment)
nsq-NSCLC (n=9)
sq-NSCLC [A] (n=12 )
sq-NSCLC [B] (n=5 )
SCLC (n=8)
Total
(N=34)
PR
4 (44.4)
9 (75)
4 (80)
5 (62.5)
22 (64.7)
Confirmed PR
1 (11.1)
4 (33.3)
4 (80)
4 (50)
13 (38.2)
Unconfirmed PR
3 (33.3)
5 (41.7)
0 (0)
1 (12.5)
9 (26.5)
SD
3 (33.3)
2 (16.7)
1 (20)
2 (25)
8 (23.5)
PD
1 (11.1)
0 (0)
0 (0)
1 (12.5)
2 (5.9)
NE
1 (11.1)
1 (8.3)
0 (0)
0 (0)
2 (5.9)
Data presented as n (%).
Abbreviations: nsq-NSCLC, non-squamous non-small cell lung cancer; NE, not evaluable; PD, progressive disease; PR, partial response; SCLC, small cell lung cancer; SD, stable disease; sq-NSCLC, squamous non-small cell lung cancer.
Tislelizumab, in combination with platinum doublets, demonstrated preliminary antitumor activity and was generally well tolerated in patients with advanced lung cancer.
6f8b794f3246b0c1e1780bb4d4d5dc53
-
+
P2.01 - Advanced NSCLC (Not CME Accredited Session) (ID 950)
- Event: WCLC 2018
- Type: Poster Viewing in the Exhibit Hall
- Track:
- Presentations: 1
- Moderators:
- Coordinates: 9/25/2018, 16:45 - 18:00, Exhibit Hall
-
+
P2.01-86 - Genetic Profiling of Circulating Cell-Free DNA from Cerebrospinal Fluid and Plasma in ALK-Positive Lung Cancer with Brain Metastases (ID 13189)
16:45 - 18:00 | Author(s): Zhe Liu
- Abstract
Background
Brain metastases (BMs) occur in approximately 30% of patients with ALK-positive non-small-cell lung cancer (NSCLC), and in patients treated with crizotinib, central nervous system progression occurs in up to 70% of patients. Resistance mechanisms of BMs with ALK rearrangement remained unclear due to limited access to BMs lesions.
a9ded1e5ce5d75814730bb4caaf49419 Method
Ten NSCLC patients with BMs carrying ALK-positive in tumors determined by Ventana anti-ALK (D5F3) immunohistochemistry assay were enrolled. Cell-free DNA (cfDNA) of cerebrospinal fluid (CSF) and plasma were tested by next-generation sequencing (NGS) with 168 genes panel.
4c3880bb027f159e801041b1021e88e8 Result
Out of 10 patients, three were females and seven males aged from 29 to 57 years old (median age of 34 years old). In all of cases, CSF cytology were negative. In NGS assays, In patients with ALK-positive, fusion gene positive genes were detected in 30.0% (3/10), 80.0% (8/10) and 100% (8/8) patients of CSF cfDNA, plasma and tumor, respectively; and in ALK-positive of CSF, all of them had much higher allele fractions in CSF cfDNA than the other two media.
8eea62084ca7e541d918e823422bd82e Conclusion
For ALK-positive lung cancer with BMs, CSF may serve as liquid biopsy by detecting cfDNA within CSF to characterize the driver and resistant genes, dynamic genetic profiling of CSF would be an appropriate choice.
6f8b794f3246b0c1e1780bb4d4d5dc53
